vs
Side-by-side financial comparison of BED BATH & BEYOND, INC. (BBBY) and Orthofix Medical Inc. (OFIX). Click either name above to swap in a different company.
BED BATH & BEYOND, INC. is the larger business by last-quarter revenue ($247.8M vs $219.9M, roughly 1.1× Orthofix Medical Inc.). Orthofix Medical Inc. runs the higher net margin — -1.0% vs -6.6%, a 5.6% gap on every dollar of revenue. On growth, BED BATH & BEYOND, INC. posted the faster year-over-year revenue change (6.9% vs 2.0%). Orthofix Medical Inc. produced more free cash flow last quarter ($16.8M vs $-12.8M). Over the past eight quarters, Orthofix Medical Inc.'s revenue compounded faster (8.0% CAGR vs -21.1%).
Bed Bath & Beyond was an American big-box retail chain specializing in housewares, furniture, and specialty items. Headquartered in Union, New Jersey, the chain operated stores in the United States and Canada, and was once counted among the Fortune 500 and the Forbes Global 2000. The chain filed for Chapter 11 bankruptcy in April 2023 and liquidated all of its remaining stores, with the last closing on July 30, 2023. Following the retail chain's liquidation, its name was adopted by online ret...
Orthofix Medical Inc. is a global medical device firm specializing in orthopedic care. It develops, manufactures and sells spinal implants, trauma care products, bone growth stimulation therapies and regenerative medicine offerings, serving orthopedic surgeons and healthcare providers across North America, Europe and Asia Pacific.
BBBY vs OFIX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.8M | $219.9M |
| Net Profit | $-16.4M | $-2.2M |
| Gross Margin | 23.9% | 71.1% |
| Operating Margin | 68.8% | 0.2% |
| Net Margin | -6.6% | -1.0% |
| Revenue YoY | 6.9% | 2.0% |
| Net Profit YoY | 58.9% | 92.4% |
| EPS (diluted) | $-0.24 | $-0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $247.8M | — | ||
| Q4 25 | $273.4M | $219.9M | ||
| Q3 25 | $257.2M | $205.6M | ||
| Q2 25 | $282.3M | $203.1M | ||
| Q1 25 | $231.7M | $193.6M | ||
| Q4 24 | $303.2M | $215.7M | ||
| Q3 24 | $311.4M | $196.6M | ||
| Q2 24 | $398.1M | $198.6M |
| Q1 26 | $-16.4M | — | ||
| Q4 25 | $-20.9M | $-2.2M | ||
| Q3 25 | $-4.5M | $-22.8M | ||
| Q2 25 | $-19.3M | $-14.1M | ||
| Q1 25 | $-39.9M | $-53.1M | ||
| Q4 24 | $-81.3M | $-29.1M | ||
| Q3 24 | $-61.0M | $-27.4M | ||
| Q2 24 | $-42.6M | $-33.4M |
| Q1 26 | 23.9% | — | ||
| Q4 25 | 24.6% | 71.1% | ||
| Q3 25 | 25.3% | 72.2% | ||
| Q2 25 | 23.7% | 68.7% | ||
| Q1 25 | 25.1% | 62.8% | ||
| Q4 24 | 23.0% | 69.0% | ||
| Q3 24 | 21.2% | 68.7% | ||
| Q2 24 | 20.1% | 67.8% |
| Q1 26 | 68.8% | — | ||
| Q4 25 | -4.8% | 0.2% | ||
| Q3 25 | -4.8% | -8.3% | ||
| Q2 25 | -4.4% | -7.9% | ||
| Q1 25 | -10.0% | -25.2% | ||
| Q4 24 | -11.3% | -5.3% | ||
| Q3 24 | -14.5% | -9.6% | ||
| Q2 24 | -11.8% | -12.5% |
| Q1 26 | -6.6% | — | ||
| Q4 25 | -7.6% | -1.0% | ||
| Q3 25 | -1.8% | -11.1% | ||
| Q2 25 | -6.8% | -6.9% | ||
| Q1 25 | -17.2% | -27.4% | ||
| Q4 24 | -26.8% | -13.5% | ||
| Q3 24 | -19.6% | -13.9% | ||
| Q2 24 | -10.7% | -16.8% |
| Q1 26 | $-0.24 | — | ||
| Q4 25 | $-0.26 | $-0.05 | ||
| Q3 25 | $-0.07 | $-0.57 | ||
| Q2 25 | $-0.34 | $-0.36 | ||
| Q1 25 | $-0.74 | $-1.35 | ||
| Q4 24 | $-1.68 | $-0.76 | ||
| Q3 24 | $-1.33 | $-0.71 | ||
| Q2 24 | $-0.93 | $-0.88 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $135.8M | $82.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $202.5M | $450.0M |
| Total Assets | $404.5M | $850.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $135.8M | — | ||
| Q4 25 | $175.3M | $82.0M | ||
| Q3 25 | $167.4M | $62.9M | ||
| Q2 25 | $120.6M | $65.6M | ||
| Q1 25 | $114.6M | $58.0M | ||
| Q4 24 | $159.2M | $83.2M | ||
| Q3 24 | $140.4M | $30.1M | ||
| Q2 24 | $186.2M | $26.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M |
| Q1 26 | $202.5M | — | ||
| Q4 25 | $217.6M | $450.0M | ||
| Q3 25 | $202.6M | $442.5M | ||
| Q2 25 | $130.9M | $458.3M | ||
| Q1 25 | $143.4M | $458.3M | ||
| Q4 24 | $162.7M | $503.1M | ||
| Q3 24 | $196.2M | $525.9M | ||
| Q2 24 | $250.4M | $546.0M |
| Q1 26 | $404.5M | — | ||
| Q4 25 | $425.5M | $850.6M | ||
| Q3 25 | $414.4M | $832.6M | ||
| Q2 25 | $358.1M | $837.2M | ||
| Q1 25 | $363.7M | $823.1M | ||
| Q4 24 | $402.0M | $893.3M | ||
| Q3 24 | $428.3M | $867.9M | ||
| Q2 24 | $496.8M | $882.0M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.8M | $27.7M |
| Free Cash FlowOCF − Capex | $-12.8M | $16.8M |
| FCF MarginFCF / Revenue | -5.2% | 7.6% |
| Capex IntensityCapex / Revenue | — | 4.9% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-24.8M | $-1.3M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $-11.8M | — | ||
| Q4 25 | $-6.5M | $27.7M | ||
| Q3 25 | $-15.1M | $12.4M | ||
| Q2 25 | $15.8M | $11.6M | ||
| Q1 25 | $-50.9M | $-18.4M | ||
| Q4 24 | $-21.7M | $23.7M | ||
| Q3 24 | $-42.1M | $11.7M | ||
| Q2 24 | $-75.9M | $9.0M |
| Q1 26 | $-12.8M | — | ||
| Q4 25 | $-8.6M | $16.8M | ||
| Q3 25 | $-17.4M | $2.5M | ||
| Q2 25 | $14.0M | $4.5M | ||
| Q1 25 | $-52.1M | $-25.1M | ||
| Q4 24 | $-24.7M | $15.2M | ||
| Q3 24 | $-45.5M | $6.3M | ||
| Q2 24 | $-80.4M | $-360.0K |
| Q1 26 | -5.2% | — | ||
| Q4 25 | -3.2% | 7.6% | ||
| Q3 25 | -6.8% | 1.2% | ||
| Q2 25 | 5.0% | 2.2% | ||
| Q1 25 | -22.5% | -13.0% | ||
| Q4 24 | -8.1% | 7.0% | ||
| Q3 24 | -14.6% | 3.2% | ||
| Q2 24 | -20.2% | -0.2% |
| Q1 26 | — | — | ||
| Q4 25 | 0.8% | 4.9% | ||
| Q3 25 | 0.9% | 4.8% | ||
| Q2 25 | 0.6% | 3.5% | ||
| Q1 25 | 0.5% | 3.5% | ||
| Q4 24 | 1.0% | 4.0% | ||
| Q3 24 | 1.1% | 2.7% | ||
| Q2 24 | 1.1% | 4.7% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BBBY
Segment breakdown not available.
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
